12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Advate octocog alfa regulatory update

Baxter said that EMA approved a label update for Advate octocog alfa from Baxter to include data from a Phase IV prophylaxis trial, which compared standard and pharmacokinetic-guided prophylaxis dosing regimens vs. on-demand treatment with the hemophilia A...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >